- 1 COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years COVID-
- 2 NET, 13 states, January 1 July 24, 2021
- 3 Authors:
- 4 Fiona P. Havers, MD, MHS<sup>1,2</sup>; Huong Pham, MPH<sup>1</sup>; Christopher A. Taylor, PhD<sup>1</sup>; Michael Whitaker, MPH<sup>1</sup>;
- 5 Kadam Patel, MPH<sup>1,3</sup>; Onika Anglin, MPH<sup>1,3</sup>; Anita K. Kambhampati, MPH<sup>1</sup>; Jennifer Milucky, MSPH<sup>1</sup>;
- 6 Elizabeth Zell, MStat<sup>1,4</sup>; Shua J. Chai, MD, MPH<sup>5,6</sup>; Pam Daily Kirley, MPH<sup>6</sup>; Nisha B. Alden, MPH<sup>7</sup>; Isaac
- Armistead, MD MPH<sup>7</sup>; Kimberly Yousey-Hindes, MPH, CPH<sup>8</sup>; James Meek, MPH<sup>8</sup>; Kyle P. Openo, DrPH<sup>9,10</sup>;
- 8 Evan J. Anderson, MD<sup>10,11,12</sup>; Libby Reeg, MPH<sup>13</sup>; Alexander Kohrman, MPH<sup>13</sup>; Ruth Lynfield, MD<sup>14</sup>;
- 9 Kathryn Como-Sabetti, MPH<sup>14</sup>; Elizabeth M. Davis, MA<sup>15</sup>; Cory Cline, MPH<sup>15</sup>; Alison Muse, MPH<sup>16</sup>; Grant
- Barney, MPH<sup>16</sup>; Sophrena Bushey, MHS<sup>17</sup>; Christina B. Felsen, MPH<sup>17</sup>; Laurie M. Billing, MPH<sup>18</sup>; Eli Shiltz,
- 11 MPH<sup>18</sup>; Melissa Sutton, MD, MPH<sup>19</sup>; Nasreen Abdullah, MD, MPH<sup>19</sup>; H. Keipp Talbot, MD, MPH<sup>20</sup>; William
- 12 Schaffner, MD<sup>20</sup>; Mary Hill, MPH<sup>21</sup>; Andrea George, MPH<sup>21</sup>; Bhavini Patel Murthy, MD<sup>1,2</sup>; Meredith
- 13 McMorrow, MD, MPH<sup>1,2</sup>
- 14 Affiliations:
- 15 <sup>1</sup> CDC COVID-19 Response, Atlanta, GA
- <sup>2</sup> United States Public Health Service Commissioned Corps, Rockville, MD
- 17 <sup>3</sup> General Dynamics Information Technology, Atlanta, GA
- 18 <sup>4</sup> Stat-Epi Associates, Inc., Ponte Vedra Beach, FL
- 19 <sup>5</sup> Division of State and Local Readiness, Center for Preparedness and Response, Centers for Disease
- 20 Control and Prevention, Atlanta, GA
- 21 <sup>6</sup> California Emerging Infections Program, Oakland, CA
- <sup>7</sup> Colorado Department of Public Health and Environment, Denver, CO
- 23 \*Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT
- <sup>9</sup> Division of Infectious Diseases, School of Medicine, Emory University, Atlanta, GA
- 25 Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA
- 26 <sup>11</sup> Departments of Medicine and Pediatrics, Emory School of Medicine, Atlanta, GA
- 27 Lanta Veterans Affairs Medical Center, Atlanta, GA
- 28 <sup>13</sup> Michigan Department of Health and Human Services, Lansing, MI
- 29 <sup>14</sup> Minnesota Department of Health, St. Paul, MN
- 30 15 New Mexico Department of Health, Santa Fe, NM
- 31 <sup>16</sup> New York State Department of Health, Albany, NY
- 32 <sup>17</sup> University of Rochester School of Medicine and Dentistry, Rochester, NY
- 33 <sup>18</sup> Ohio Department of Health, Columbus, OH
- 34 <sup>19</sup> Public Health Division, Oregon Health Authority, Portland, OR
- 35 <sup>20</sup> Vanderbilt University Medical Center, Nashville, TN
- 36 <sup>21</sup> Salt Lake County Health Department, Salt Lake City, UT
- 39 Corresponding author:

38

- 40 Fiona Havers, MD, MHS
- 41 1600 Clifton RD, MS H24-6

42 Atlanta, GA 30329

44

45

43 Phone: 404-639-5062; Email: <a href="mailto:fhavers@cdc.gov">fhavers@cdc.gov</a>

- 46 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
- 47 represent the views of the U.S. Centers for Disease Control and Prevention.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Abstract Background: As of August 21, 2021, >60% of the U.S. population aged ≥18 years were fully vaccinated with vaccines highly effective in preventing hospitalization due to Coronavirus Disease-2019 (COVID-19). Infection despite full vaccination (vaccine breakthrough) has been reported, but characteristics of those with vaccine breakthrough resulting in hospitalization and relative rates of hospitalization in unvaccinated and vaccinated persons are not well described, including during late June and July 2021 when the highly transmissible Delta variant predominated. Methods: From January 1–June 30, 2021, cases defined as adults aged ≥18 years with laboratoryconfirmed Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2) infection were identified from >250 acute care hospitals in the population-based COVID-19-Associated Hospitalization Surveillance Network (COVID-NET). Through chart review for sampled cases, we examine characteristics associated with vaccination breakthrough. From January 24-July 24, 2021, state immunization information system data linked to both >37,000 cases representative cases and the defined surveillance catchment area population were used to compare weekly hospitalization rates in vaccinated and unvaccinated individuals. Unweighted case counts and weighted percentages are presented. **Results:** From January 1 – June 30, 2021, fully vaccinated cases increased from 1 (0.01%) to 321 (16.1%) per month. Among 4,732 sampled cases, fully vaccinated persons admitted with COVID-19 were older compared with unvaccinated persons (median age 73 years [Interquartile Range (IQR) 65-80] v. 59 years [IQR 48-70]; p<0.001), more likely to have 3 or more underlying medical conditions (201 (70.8%) v. 2,305 (56.1%), respectively; p<0.001) and be residents of long-term care facilities [37 (14.5%) v. 146 (5.5%), respectively; p<0.001]. From January 24 – July 24, 2021, cumulative hospitalization rates were 17 times higher in unvaccinated persons compared with vaccinated persons (423 cases per 100,000 population v. 26 per 100,000 population, respectively); rate ratios were 23, 22 and 13 for those aged 18-49, 50-64,

and ≥65 years respectively. For June 27 – July 24, hospitalization rates were ≥10 times higher in unvaccinated persons compared with vaccinated persons for all age groups across all weeks.

Conclusion: Population-based hospitalization rates show that unvaccinated adults aged ≥18 years are 17 times more likely to be hospitalized compared with vaccinated adults. Rates are far higher in unvaccinated persons in all adult age groups, including during a period when the Delta variant was the predominant strain of the SARS-CoV-2 virus. Vaccines continue to play a critical role in preventing serious COVID-19 illness and remain highly effective in preventing COVID-19 hospitalizations.

### Introduction

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

As of August 21, 2021, 170 million people in the United States were fully vaccinated against COVID-19, including >62% of the population aged ≥18 years. <sup>2</sup> Consistent with other studies, data from the Centers for Disease Control and Prevention's (CDC) Coronavirus Disease 2019-Associated Hospitalization Surveillance Network (COVID-NET) have previously shown that all three vaccine products currently available are highly effective in preventing hospitalization in adults aged ≥65 years. <sup>3,4</sup> Infections in fully vaccinated persons (i.e., vaccine breakthroughs cases) are expected, <sup>5</sup> even in the setting of highly effective vaccines. While most infections occurring in fully vaccinated individuals have been mild or asymptomatic, 5 more serious SARS-CoV-2 infections can occur in fully vaccinated individuals. 4 However, the characteristics of fully vaccinated patients hospitalized with COVID-19 and factors associated with risk of vaccine breakthrough have not been well described. Using COVID-NET data representing >67,000 COVID-19-associated hospitalizations from January–June 2021, we compare characteristics of persons hospitalized with laboratory-confirmed SARS-CoV-2 virus infection by vaccination status and assess characteristics of hospitalized cases with vaccination breakthrough. We also compare clinical outcomes between unvaccinated and fully vaccinated persons admitted for COVID-19-associated illness. We use state immunization information system (IIS) linked to both hospitalized cases with laboratory-confirmed SARS-CoV-2 infection and the population of the defined COVID-NET catchment area to compare weekly population-based hospitalization rates in vaccinated and unvaccinated individuals, including for late June and July 2021, a period when the highly-transmissible Delta variant was the predominant strain circulating.6

## Methods

## COVID-NET description and data collected for all COVID-NET Cases

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

COVID-NET is a population-based surveillance system of laboratory-confirmed COVID-19-associated hospitalizations comprising 99 counties in 14 states (California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah) and covering approximately 10% of the US population. Hospitalized patients residing in a surveillance catchment area with a positive molecular or rapid antigen detection test for SARS-CoV-2 during hospitalization or within 14 days before admission are included as COVID-NET cases. One site (lowa) does not have access to the state IISs and was excluded from this analysis. Basic demographic information, including age, race and Hispanic ethnicity, sex, hospital admission date, and evidence of a positive SARS-CoV-2 test are transmitted weekly on all patients. Since few children were fully vaccinated during the analysis period, this analysis was limited to adult cases aged ≥18 years. **COVID-NET Sampling/Weighting Methodology** Detailed data on patient demographics, COVID-19 vaccination status, primary reason for admission, select underlying medical conditions, and clinical outcomes, including ICU admission and death, are collected on a representative sample of patients stratified by age and site. To select sampled cases, random numbers are generated and assigned to each case. Sampling weights are based on the probability of selection and adjusted for non-response; sample sizes vary by surveillance month, site and age group and are based on the total number of cases identified in each of these strata. 8 Monthly demographic and clinical data through June 2021 were the most recent data available at the time of this study. Vaccination definitions, weighting of cases with known vaccination status Fully vaccinated cases were defined as having a positive SARS-CoV-2 test ≥14 days after either the second dose of a 2-dose series or after one dose of a single dose series. Partial vaccination was defined

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

as ≥14 days after a single dose through <14 days after the second dose in a 2-dose series. If the SARS-CoV-2 test date was not available, hospital admission date was used. Partially vaccinated patients and patients with positive tests <14 days after one vaccine dose, regardless of type, were excluded from further analyses. Vaccination status for both hospitalized cases and the underlying population was determined by state IIS data, as previously described.<sup>3</sup> We collected COVID-19 vaccination status (doses, dates administered, and product) from state IISs for all sampled COVID-NET cases. Some sites expanded collection of vaccination status to non-sampled cases, which were included for analysis of demographic factors and population-based rates associated with vaccination if all cases in a single month and age group had vaccination status available ("vaccine sample"). For fully vaccinated sampled cases only, COVID-NET personnel reviewed state health department electronic laboratory records and other data sources for a positive SARS-CoV-2 tests predating the test associated with the current hospitalization. This was done to exclude those who were reinfected or had prolonged viral shedding from a prior SARS-CoV-2 infection that predated full vaccination and, therefore, did not meet the definition of vaccine breakthrough (Supplementary Table 2). Data on prior positive SARS-CoV-2 tests were not available for unvaccinated persons. Comparison of Clinical Characteristics and Outcomes among a Weighted Sample of Fully Vaccinated and Unvaccinated Hospitalized Cases with COVID-19 For all sampled cases, trained surveillance staff conduct medical chart abstractions using a standard case report form. We compared demographic information, underlying medical conditions, clinical outcomes, signs and symptoms at admission, and reasons for admission between unvaccinated and fully vaccinated sampled cases ("comparison sample"). Underlying medical conditions were categorized into major groups (Supplementary Table 1). Two physicians reviewed reason for admission and symptoms, and

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

those cases whose reason for admission might not have been primarily related to COVID-19, despite receiving a positive SARS-CoV-2 laboratory test, were excluded from the comparison sample.<sup>3</sup> We used multivariable logistic regression to examine factors associated with vaccine breakthrough cases; models included age, race and Hispanic ethnicity, long-term care facility (LTCF) residence, and underlying medical conditions. We also used multivariable logistic regression to examine the association of vaccination with severe COVID-19, defined as ICU admission or in-hospital death. Because older adults were eligible for vaccination earlier than other age groups and older age has been associated with increased risk of vaccine breakthrough with other infections, we stratified all models, analyzing those aged <65 and ≥65 years separately. Description of Population-Based COVID-19-Associated Hospitalization Rates among Unvaccinated and Vaccinated Persons We collected a minimum set of data on all identified cases to produce weekly hospitalization rates (https://gis.cdc.gov/grasp/COVIDNet/COVID19 3.html) for all COVID-NET cases. Incidence rates were calculated using the National Center for Health Statistics' vintage 2019 bridge-race postcensal population estimates for the counties included in COVID-NET surveillance. 10 To determine populationbased rates of hospitalization by vaccination status per 100,000 persons ≥18 years of age, county-level coverage in the COVID-NET catchment area was estimated using population denominators. Vaccination status was classified as described above for hospitalized cases using the vaccine sample; weekly population-based rates were calculated based on denominators that changed weekly depending on the vaccination status of individuals in the underlying population. Rate ratios were calculated for all fully vaccinated and unvaccinated cases who met the case definition, regardless of prior SARS-CoV-2 test results or reason for admission; overall rates for those ≥18 years were standardized to the underlying population. We excluded partially vaccinated persons from rate calculations. For analyses comparing

hospitalization rates in unvaccinated with vaccinated persons only, data through the week ending July 24, 2021 were included, as they were the most recent data available at the time of this study. Weeks in which the Delta variant was estimated to cause >50% of new SARS-COV-2 infections, June 27 – July 24, 2021, were examined. A method for formally calculating vaccine effectiveness from COVID-NET data has been published; VE estimates will be included in a forthcoming manuscript.

## Statistical Analysis

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Data from all cases aged ≥18 years and hospitalized with laboratory-confirmed COVID-19 during January 1-June 30, 2021 with linked vaccine registry data were used to describe the vaccination status of hospitalized cases by age, sex, race and Hispanic ethnicity, and month of admission. The comparison sample used in multivariable models included age groups (18–49, 50–64, ≥65 years), sex, and race and ethnicity; models incorporated clustering by site to account for geographic differences. Other variables with p-values <0.10 in bivariate analyses were included in the multivariable analyses. Model fit was assessed with Quasi-likelihood under Independence Model Criterion (QIC). Log-linked Poisson generalized estimating equations regression with an independent working correlation structure was used to generate adjusted risk ratios (aRR) and 95% confidence intervals (CI). Data were analyzed using SAS survey procedures to account for sampling weights. Unweighted case counts and weighted percentages are presented unless otherwise noted. Proportions by month with 95% confidence intervals are presented for binary measures, and medians with interquartile ranges for continuous measures. We used Taylor series linearization methods for variance estimation. All analyses were conducted using SAS 9.4 software (SAS Institute Inc., Cary, NC). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC

policy (see e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C.

## Results

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

During January 1-June 30, 2021, there were 67,311 laboratory-confirmed COVID-19-associated hospitalized cases ≥18 years identified in COVID-NET and meeting the case definition, among whom a representative sample of 35,846 had vaccination data linked to state vaccination registries (vaccine sample) (Supplementary Figure 1). Among these, 30,967 (87.6% (weighted percentages shown throughout)) were unvaccinated, 1,791 (5.0%) had received 1 dose <14 d prior to admission, 1,753 (4.4%) were partially vaccinated and 1,255 (3%) were fully vaccinated (**Table 1**). The number of cases that were fully vaccinated increased from 1 (0.0%) in January to 321 (16.1%) in June. A greater proportion of cases in older age groups were fully vaccinated; 32% of hospitalized cases aged ≥65 years in June were fully vaccinated (Supplementary Figure 2). Among a representative sample of 6,115 hospitalized adults aged ≥18 years, the following were excluded (unweighted percentages shown for excluded cases): 282 (4.6%) who had received one dose of vaccine <14 days prior to the positive SARS-CoV-2 test, 286 (4.7%) who were partially vaccinated, 14 (0.2%) with unknown vaccination status, and 33 (0.5%) cases with incomplete data. Among remaining the cases (n=5,550), 390 were fully vaccinated and 5,160 were unvaccinated; among fully vaccinated cases, 52/390 (13%) had evidence of prior SARS-CoV-2 positive tests and were also excluded. An additional 716 (13%) of the remaining 5,448 cases were excluded as their reason for admission might not have been primarily related to COVID-19; the proportion of cases excluded for this reason was similar among the remaining vaccinated cases compared with unvaccinated cases ((46/338 (14%) v. 670/5110 (13%), respectively; p-value = 0.79)). (Supplementary Figure 1). The comparison sample was thus restricted to the remaining 4,732 cases with hospitalization associated primarily with COVID-19 illness, including 4,440 unvaccinated and 292 fully vaccinated cases (Table 2). Among fully vaccinated cases, the median time from full vaccination status until hospital admission was 42 days (IQR 28–68). Among all adults aged ≥18 years, fully vaccinated cases were older when compared to unvaccinated cases [median age 73 years (IQR 65-80) v. 59 years (IQR 48-70); p<0.001] and more

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

likely to be LTCF residents [37 (14.5%) v. 146 (5.5%), respectively; p<0.001]. In addition, 69 (32.1%) fully vaccinated cases were more likely to be immunosuppressed compared with 442 (11.3%) unvaccinated cases (p<0.001); these fully vaccinated immunosuppressed cases included 25 (36%) and 14 (20%) cases with solid organ malignancy and a history of a solid organ transplant, respectively. Vaccinated cases were also more likely to have 3 or more underlying medical conditions compared with unvaccinated cases (201 (70.8%) v. 2,305 (56.1%), respectively; p<0.001). On multivariable analysis, after adjusting for, age, sex, race and Hispanic ethnicity, LTCF status, and underlying medical conditions, and excluding those whose reason for hospitalization was likely not primarily COVID-19-related, fully vaccinated patients aged ≥65 years, were more likely to be immunosuppressed (aRR: 3.2 (95% CI 2.0-5.1) and to be obese (aRR: 1.6 (95% CI 1.0-2.5) than unvaccinated patients (Figure 1B). Fully vaccinated patients aged <65 years were more likely to have underlying neurologic and gastrointestinal/liver diseases (aRRs: 1.6 (95% CI 1.0-2.6) and 2.3 (95% CI 1.0-5.4), respectively). The number and proportion of fully vaccinated persons admitted to the ICU was similar to unvaccinated persons (60 (20.6%) v. 931 (20.0%), respectively; p-value=0.66), as were results for in-hospital death (23 (7.5%) v. 342 (8.4%), respectively; p-value=0.69). Median length of stay was significantly longer in fully vaccinated persons (median 5 days (IQR 3-8) v. 4 days (IQR 2-9), respectively; p<0.001) (Table 2). On multivariable analysis adjusting for age, sex, race, and underlying medical conditions, being fully vaccinated was significantly associated with reduced risk of severe disease (i.e. ICU admission and/or death) in those aged <65 years (aRR 0.8 (95% CI 0.6-1.0), but this association was not significant in those aged ≥65 years (aRR 1.1 (95% CI 0.7–1.6) (Supplementary Tables 3A-B).

Population-based rates of COVID-19-associated hospitalization by vaccination status

During the study period, the percentage of persons aged ≥18 years in the COVID-NET catchment area who were fully vaccinated increased from 0.9% in January to 57% in June 2021. The COVID-NET catchment population that was fully vaccinated varied by week and age group (Supplementary Figure 3A–D). From January 24–July 24, 2021, the age-adjusted cumulative hospitalization rate among persons ≥18 years of age was 432 hospitalized cases per 100,000 unvaccinated persons compared with 26 per 100,000 fully vaccinated persons, a 17-fold higher cumulative rate (Figure 2A); cumulative rate ratios were 26, 22 and 13 for those aged 18–49, 50–64, and ≥65 years respectively (Supplementary Table 4). The weekly overall COVID-NET hospitalization rates tracked closely with the hospitalization rates of the unvaccinated population earlier in the study period, but as vaccination coverage increased, the overall rate started to converge with the rate in the fully vaccinated population (Figure 2B, Figure 3A-C). The weekly rate ratio varied each week with no clear pattern (range in those aged ≥18 years: 6–31). For June 27–July 24, hospitalization rates were ≥10 times higher in unvaccinated persons compared with vaccinated persons for all age groups across all weeks (rate ratio range in those aged ≥18 years: 12-19) (Supplementary Table 4).

## Discussion

In this analysis using data from a representative sample of over 67,000 laboratory-confirmed COVID-19-associated hospitalizations in persons aged ≥18 years, we demonstrated that cumulative population-based rates of COVID-19-associated hospitalization were approximately 17 times higher in unvaccinated persons compared with vaccinated persons, and more than 13 times higher in adults aged ≥65 years.

Rates remained ≥10 times higher in unvaccinated persons compared with vaccinated persons in all adult age groups across all weeks in late June and July 2021, a period in which the Delta variant has predominated, suggesting that vaccines remain highly effective in preventing hospitalizations in all adult age groups. Those persons who were hospitalized despite being fully vaccinated were more medically fragile at baseline than those who were unvaccinated. Fully vaccinated cases were older, more likely to

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

reside in LCTFs, and had more underlying medical conditions; nearly a third (32%) had immunosuppressive conditions, compared with 11% of those who were unvaccinated. Our finding that a substantial and growing proportion of hospitalized persons were fully vaccinated is not surprising; the proportion of hospitalized cases who are fully vaccinated is expected to increase as population vaccination coverage increases. Given the high vaccination coverage, particularly in older age groups, which was more than 80% in July for those ≥65 years, the finding that 16% of hospitalized cases ≥18 years during that month were fully vaccinated is consistent with what we would expect from highly effective vaccines. This analysis demonstrated that population-based rates of hospitalization were consistently far higher in unvaccinated persons compared with fully vaccinated persons in all age groups and over time. Using detailed IIS data from of a defined population, a 17-times greater cumulative hospitalization rate in unvaccinated persons is consistent with ongoing high levels of vaccine effectiveness in preventing hospitalizations and suggests that increasing vaccination coverage can prevent serious illness and death. Some of the differences in hospitalization rates between the unvaccinated and vaccinated populations may be attributable in part to differences in mask-wearing and physical distancing between the two groups. Cumulative rate ratios were lower in older adults than younger groups, but vaccinated adults aged ≥65 years had hospitalization rates that were more than 90% lower than unvaccinated persons in the same age group; recent increases in hospitalization rates appear to be driven disproportionately by unvaccinated persons. Far higher rates of hospitalization among unvaccinated persons compared to vaccinated persons of all ages persisted in July 2021, a time when the highly-transmissible Delta variant was the predominant variant circulating and hospitalization rates among vaccinated individuals remained comparatively low and stable. Although studies have suggested that current vaccines may be less effective in preventing SARS-CoV-2 infections due to the Delta variant compared than with

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

previously circulating varians, 12-14 this analysis suggests that vaccination remains highly effective against the Delta variant in preventing severe disease resulting in hospitalization.<sup>6</sup> We demonstrated that, consistent with other studies, among hospitalized cases, vaccinated persons reflected older and more medically fragile populations that were prioritized to receive the vaccine early. Those aged ≥75 years, LTCF residents, those who are immunocompromised or have multiple underlying conditions may be among the most vulnerable to severe infection and the least likely to mount an adequate immune response to immunization; given early receipt of the vaccine, these populations may also be vulnerable to any potential waning of effectiveness over time. 4,15,16 Increased vulnerability to severe disease resulting in hospitalization, even if fully vaccinated, supports the importance of vaccination among LCTF staff and visitors in protecting persons vulnerable to severe COVID-19. The high proportion of fully vaccinated patients who were immunocompromised also supports the recent recommendation for a third vaccine dose for immunocompromised adults who had previously received mRNA vaccines, although more research is needed to understand the extent to which an additional dose of vaccine results in increased protection in immunocompromised individuals. 17 In the outpatient setting, vaccination likely attenuates disease severity if a breakthrough infection occurs, 5 but our analysis showed that conditional on being hospitalized, vaccinated persons were still at a high risk of severe outcomes, with more than 20% admitted to the ICU. We did not find any clear difference in the risk for ICU admission or in-hospital death between vaccinated and unvaccinated persons. This may reflect the fact that those who were hospitalized despite vaccination may be more vulnerable to severe infection at baseline than those who are not vaccinated. In addition, unidentified confounders that are not well-accounted for may affect these results; further detailed analyses examining clinical presentation and outcomes are planned.

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

This analysis has several limitations. Although COVID-NET covers approximately 10% of the U.S. population, our findings may not be generalizable to the entire country. Since SARS-CoV-2 testing was conducted at the discretion of healthcare professionals, COVID-NET may not have captured all COVID-19-associated hospitalizations. The primary reason for hospital admission was not always clear, and some patients who met the COVID-NET case definition may have been hospitalized for reasons that were not primarily related to COVID-19. The inclusion of these hospitalizations in rate calculations could have resulted in an overestimation of hospitalization rates for COVID-19 for both unvaccinated and vaccinated persons. Using population-based hospitalization rates, our study found unvaccinated adults are hospitalized at rates that are 17 times higher than for vaccinated adults in the same catchment areas. Rates of COVID-19-associated hospitalizations are far higher in unvaccinated persons in all adult age groups, even during a period when the highly-transmissible Delta variant was the predominant circulating variant. 12 Population-based hospitalization rates will be a critical metric in the continued assessment of the effectiveness of vaccines in the population, and complementary to vaccine effectiveness studies using other methods. <sup>4,18</sup> The much higher rates observed in unvaccinated persons compared to vaccinated adults suggest that vaccines remain highly effective in preventing hospitalization for COVID-19 illness. Continuing to increase vaccination coverage in all eligible groups is crucial to preventing severe COVID-19.

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

Funding: This work was supported by the Centers of Disease Control and Prevention through an Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State and Territorial Epidemiologists cooperative agreement (grant NU38OT000297-02-00). Acknowledgments: Roxanne Archer, Susan Brooks, Monica Napoles, Jeremy Roland, Tiffany Tsukuda, CA Emerging Infections Program; Arthur Reingold, University of California, Berkeley; Rachel Herlihy, Breanna Kawasaki, Colorado Department of Public Health and Environment; Ann Basting, Tessa Carter, Maria Correa, Daewi Kim, Carol Lyons, Amber Maslar, Julie Plano, Connecticut Emerging Infections Program, Yale School of Public Health; Katelyn Ward, Georgia Emerging Infections Program, Georgia Department of Health, Division of Infectious Diseases, School of Medicine, Emory University; Marina Bruck, Rayna Ceasar, Gracie Chambers, Taylor Eisenstein, Emily Fawcett, Asmith Joseph, Grayson Kallas, Stephanie Lehman, Jana Manning, Annabel Patterson, Allison Roebling, Chandler Surell, Georgia Emerging Infections Program, Georgia Department of Health, Veterans Affairs Medical Center, Foundation for Atlanta Veterans Education and Research; David Blythe, Alicia Brooks, Elisabeth Vaeth, Cindy Zerrlaut, Maryland Department of Health; Rachel Park, Michelle Wilson, Maryland Emerging Infections Program - The Johns Hopkins Bloomberg School of Public Health; Chloe Brown, Jim Collins, Justin Henderson, Shannon Johnson, Sue Kim, Lauren Leegwater, Sierra Peguies-Khan, Val Tellez Nunez, Michigan Department of Health and Human Services; Aaron Bieringer, Erica Bye, Richard Danila, Kristen Ehresmann, Corinne Holtzman, Sydney Kuramoto, Stephanie Meyer, Miriam Muscoplat, Rachel Ostadkar, Minnesota Department of Health; Marianne Murphy, Murtada Khalifa, Yassir Talha, CDC Foundation/New Mexico Department of Health; Melissa Judson, Sunshine Martinez, Jasmyn Sanchez, Chad Smelser, Daniel Sosin, New Mexico Department of Health; Kathy M. Angeles, Melissa Christian, Nancy Eisenberg, Emily B. Hancock, Sarah A. Khanlian, Sarah Lathrop, Wickliffe Omondi, Mayvilynne Poblete, Dominic Rudin, Yadira Salazar-Sanchez, Sarah Shrum Davis, Chelsea McMullen,

Susan Ropp, New Mexico Emerging Infections Program; Kerianne Engesser, Suzanne McGuire, Adam Rowe, Nancy Spina, New York State Department of Health; Nancy Bennett, Virginia Cafferky, Maria Gaitan, Christine Long, Thomas Peer, Kevin Popham, University of Rochester School of Medicine and Dentistry; Kylie Seeley, Oregon Health & Science University School of Medicine; Ama Owusu-Dommey, Emily Youngers, Breanna McArdle, Public Health Division; Oregon Health Authority; Kathy Billings, Katie Dyer, Anise Elie, Karen Leib, Tiffanie Markus, Terri McMinn, Danielle Ndi, Manideepthi Pemmaraju, John Ujwok, Vanderbilt University Medical Center; Ian Buchta, Amanda Carter, Ryan Chatelain, Andrew Haraghey, Laine McCullough, Jacob Ortega, Andrea Price, Tyler Riedesel, Ilene Risk, Caitlin Shaw, Melanie Spencer, Ashley Swain, Salt Lake County Health Department; Keegan McCaffrey, Utah Department of Health; Kelly Oakeson, Alessandro Rossi, Utah Public Health Laboratory

### References

360

- Garg S, Patel K, Pham H, et al. Clinical Trends Among U.S. Adults Hospitalized with COVID-19,
   March-December 2020. medRxiv 2021:2021.04.21.21255473. DOI:
   10.1101/2021.04.21.21255473.
- CDC COVID Data Tracker. Centers for Diseases Control and Prevention.
   (https://covid.cdc.gov/covid-data-tracker/#vaccinations\_vacc-total-admin-rate-total).
- Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 Vaccines in Preventing
   Hospitalization Among Adults Aged >/=65 Years COVID-NET, 13 States, February-April 2021.
   MMWR Morbidity and mortality weekly report 2021;70(32):1088-1093. DOI:
   10.15585/mmwr.mm7032e3.
- Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for
   Preventing Covid-19 Hospitalizations in the United States. Clinical infectious diseases: an official
   publication of the Infectious Diseases Society of America 2021. DOI: 10.1093/cid/ciab687.
- Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. The New England journal of medicine 2021;385(4):320-375 329. DOI: 10.1056/NEJMoa2107058.
- 376 6. CDC Data Tracker: Variant Proportions. Centers for Disease Control and Prevention.
  377 (<a href="https://covid.cdc.gov/covid-data-tracker/#variant-proportions">https://covid.cdc.gov/covid-data-tracker/#variant-proportions</a>).
- Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients
   Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 COVID-NET, 14 States,
   March 1-30, 2020. MMWR Morbidity and mortality weekly report 2020;69(15):458-464. DOI:
   10.15585/mmwr.mm6915e3.
- 382 8. Garg S, Patel K, Pham H, et al. Clinical Trends Among U.S. Adults Hospitalized With COVID-19, 383 March to December 2020: A Cross-Sectional Study. Annals of internal medicine 2021. DOI: 384 10.7326/M21-1991.
- McClung N, Chamberland M, Kinlaw K, et al. The Advisory Committee on Immunization
   Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine United States,
   2020. MMWR Morbidity and mortality weekly report 2020;69(47):1782-1786. DOI:
   10.15585/mmwr.mm6947e3.
- 389 10. U.S. Census Populations With Bridged Race Categories390 (<a href="https://www.cdc.gov/nchs/nvss/bridged\_race.htm">https://www.cdc.gov/nchs/nvss/bridged\_race.htm</a>).
- Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines
   Against COVID-19 Among Hospitalized Adults Aged >/=65 Years United States, January-March
   2021. MMWR Morbidity and mortality weekly report 2021;70(18):674-679. DOI:
   10.15585/mmwr.mm7018e1.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the
   B.1.617.2 (Delta) Variant. The New England journal of medicine 2021. DOI:
   10.1056/NEJMoa2108891.
- S. Nanduri TP, G. Derado et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in
   Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During
   Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant National Healthcare
   Safety Network, March 1-August 1, 2021. MMWR Morbidity and mortality weekly report 2021.
- 402 14. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021:2021.08.06.21261707. DOI: 10.1101/2021.08.06.21261707.

- 405 15. Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices'
   406 Updated Interim Recommendation for Allocation of COVID-19 Vaccine United States,
   407 December 2020. MMWR Morbidity and mortality weekly report 2021;69(5152):1657-1660. DOI:
   408 10.15585/mmwr.mm695152e2.
- 409 16. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough:
  410 clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical
  411 microbiology and infection: the official publication of the European Society of Clinical
  412 Microbiology and Infectious Diseases 2021. DOI: 10.1016/j.cmi.2021.06.036.
- 413 17. Media Statement from CDC Director Rochelle P. Walensky, MD, MPH, on Signing the Advisory
  414 Committee on Immunization Practices' Recommendation for an Additional Dose of an mRNA
  415 COVID-19 Vaccine in Moderately to Severely Immunocompromised People. CDC.
- Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers Eight U.S. Locations, December 2020-March 2021. MMWR Morbidity and mortality weekly report 2021;70(13):495-500. DOI: 10.15585/mmwr.mm7013e3.

#### Tables

Table 1. Demographics of a representative sample of hospitalized adults ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States 15

Table 2. Demographics, underlying conditions, reason for admission, and clinical outcomes among a representative sample of unvaccinated and fully vaccinated hospitalized adults aged ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1– June 30, 2021, stratified by age (<65 and ≥65 years) and restricted to those with COVID-19-associated hospitalization as the likely primary reason for admission — COVID-NET, 13 States<sup>a</sup>

#### **Figures**

Figure 1. Multivariable model<sup>a</sup> assessing factors associated with full vaccination status in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged A) <65 years and B) ≥65 years — COVID-NET, 13 States<sup>b</sup>

Figure 2. Age-adjusted population-based rates of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults ≥18 years of age admitted January 24–June 26, 2021, A) cumulative and B) by week of admission — COVID-NET, 13 States b

Figure 3. Age-specific population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults ≥18 years of age admitted January 24–July 24, 2021, by week of admission and age A) 18–49 years B) 50–64 years and C) ≥65 years — COVID-NET, 13 States<sup>b</sup>

# Supplementary material

**Supplementary Table 1. Categorization of Underlying Medical Conditions** 

Supplementary Table 2. Characteristics of fully vaccinated cases who had a prior positive SARS-CoV-2 test compared with fully vaccinated cases with no evidence of prior infection, among adults ≥ 18 years admitted January 1–June 30, 2021 — COVID-NET, 13 States<sup>a</sup>

Supplementary Table 3A. Multivariable model<sup>a</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged <65 years — COVID-NET, 13 States<sup>b</sup>

Supplementary Table 3B. Multivariable model<sup>a</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged ≥65 years — COVID-NET, 13 States<sup>b</sup>

Supplementary Table 4. Rate ratios of COVID-19-associated hospitalizations in unvaccinated vs vaccinated patients among all adults aged ≥18 years and by age group <sup>a</sup>, January 24–June 26, 2021 — COVID-NET, 13 States <sup>b</sup>

### **Supplementary Figures**

Supplementary Figure 1. Selection of cases for analysis of adults ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States<sup>a</sup>

Supplementary Figure 2. Proportion of adults ≥18 years with COVID-19-associated hospitalizations admitted January 1 – June 30, 2021 who are fully vaccinated, by age group and month of admission — COVID-NET, 13 States

Supplementary Figure 3. COVID-NET catchment population by vaccination status and week, used as denominator in population-based-rate calculations among A) all adults aged ≥18 years, B) 18–49 years, C) 50–64 years, and D) ≥65 years — COVID-NET, January 24–July 24, 2021

# Tables

Table 1. Demographics of a representative sample of hospitalized adults aged ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization admitted January 1–June 30, 2021, by vaccination status — COVID-NET, 13 States to the sample of hospitalization status admitted to the samp

Characteristics	Adults ≥18 years	Unvaccinated n (weighted %)	Vaccinated <14 days prior to positive test n (weighted %)°	Partially vaccinated <sup>d</sup> n (weighted %)	Fully vaccinated n (weighted %)
Total <sup>e</sup>	35,766	30,967 (87.6)	1,791 (5.0)	1,753 (4.4)	1,255 (3.0)
Age group (median, IQR)	60 (46–72)	58 (45–70)	69 (59–80)	71 (61–82)	72 (63–81)
18–49 years	10,979	10,342 (95.1)	285 (2.4)	197 (1.4)	155 (1.2)
50–64 years	10,407	9,265 (90.9)	507 (4.0)	396 (3.5)	239 (1.6)
65–74 years	6,686	5,573 (82.9)	401 (6.9)	400 (5.8)	312 (4.4)
75–84 years	4,788	3,692 (79.4)	343 (6.1)	428 (7.4)	325 (7.1)
≥85 years	2,906	2,095 (74.2)	255 (11.5)	332 (9.4)	224 (4.9)
Sex					
Male	17,737	15,357 (87.3)	895 (5.3)	866 (4.2)	619 (3.1)
Female	18,029	15,610 (87.8)	896 (4.8)	887 (4.5)	636 (3.0)
Race and Hispanic ethnicity <sup>f</sup>					
Black	8,099	7,277 (91.0)	349 (3.6)	319 (3.6)	154 (1.8)
White	16,355	13,594 (84.9)	916 (5.4)	1,019 (5.4)	826 (4.3)
Hispanic or Latino	6,253	5,691 (90.1)	251 (5.9)	187 (2.3)	124 (1.6)
American Indian/Alaska Native	355	309 (83.8)	8 (7.9)	18 (5.3)	20 (3.0)
Asian/Pacific Islander	1,967	1,690 (85.5)	128 (6.7)	96 (4.9)	53 (2.9)
Other/Unknown	2,385	2,096 (89.0)	116 (4.4)	101 (4.3)	72 (2.4)

Characteristics	Adults ≥18 years	Unvaccinated n (weighted %)	Vaccinated <14 days prior to positive test n (weighted %)°	Partially vaccinated <sup>d</sup> n (weighted %)	Fully vaccinated n (weighted %)
Month of admission					
January	9,136	8,648 (93.9)	347 (4.7)	140 (1.3)	1 (0.0)
February	7,549	6,682 (89.0)	383 (4.1)	437 (6.3)	47 (0.6)
March	5,899	4,963 (85.2)	385 (6.0)	382 (5.7)	169 (3.1)
April	6,468	5,232 (82.0)	452 (6.7)	469 (6.7)	315 (4.6)
May	4,673	3,855 (81.5)	179 (4.2)	237 (5.3)	402 (9.0)
June	2,041	1,587 (76.6)	45 (2.5)	88 (4.9)	321 (16.1)

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network; IQR = interquartile range.

<sup>&</sup>lt;sup>a</sup>Percentages are weighted and represent row percentages

<sup>&</sup>lt;sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>&</sup>lt;sup>c</sup>This group is excluded from further analyses.

<sup>&</sup>lt;sup>d</sup>Received one dose of two-dose series (for Pfizer/BioNTech and Moderna). This group is excluded from further analyses.

<sup>&</sup>lt;sup>e</sup>80 additional cases were excluded from all analyses due to unknown vaccination status

fRace and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), non-Hispanic Asian or Pacific Islander (Asian/Pacific Islander), non-Hispanic American Indian or Alaska Native (American Indian/Alaska Native) and Other/Unknown. If ethnicity was unknown (8% of cases), non-Hispanic ethnicity was assumed.

Table 2. Demographics, underlying conditions, reason for admission, and clinical outcomes among a representative sample of unvaccinated and fully vaccinated hospitalized adults aged ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1– June 30, 2021, stratified by age (<65 and ≥65 years) and restricted to those with COVID-19-associated hospitalization as the likely primary reason for admission — COVID-NET, 13 States<sup>a</sup>

		Adults	≥18 years			<65	years		≥65 years					
Category	Total	Unvaccinated n (weighted %)		p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)			
Total	4,732	4,440 (97.1)	292 (2.9)		3,131	3,039 (98.7)	92 (1.3)		1,601	1,401 (94.8)	200 (5.2)			
Age group (median, IQR)	59 (48– 70)	,	73 (65–80)	<.001	51 (42– 58)	, ,	52 (36–60)	0.15	73 (65– 101)	73 (65–101)	77 (65–99)	0.70		
18–49 years	1,428	1,399 (26.3)	29 (8.7)		1,428	1,399 (44.5)	29 (34.9)							
50–64 years	1,703	1,640 (32.9)	63 (16.3)		1,703	1,640 (55.5)	63 (65.1)							
≥65 years	1,601	1,401 (40.8)	200 (75.0)						1,601	1,401 (100.0)	200 (100.0)			
Sex				0.63				0.32				0.70		
Male	2,420	2,275 (51.6)	145 (49.3)		1,616	1,576 (50.3)	40 (43.7)		804	699 (53.5)	105 (51.1)			
Female	2,312	2,165 (48.4)	147 (50.7)		1,515	1,463 (49.7)	52 (56.3)		797	702 (46.5)	95 (48.9)			
Race and Hispanic ethnicity <sup>c</sup>				<.001				<.001				0.34		
White	2,467	2,263 (45.9)	204 (66.3)		1,407	1,347 (37.9)	60 (61.7)		1,060	916 (57.4)	144 (67.8)			
Black	1,058	1,023 (29.3)	35 (17.5)		796	785 (33.4)	11 (14.8)		262	238 (23.4)	24 (18.5)			

		Adults	≥18 years			<65	years		≥65 years						
Category	Total	Unvaccinated n (weighted %)	vaccinated n (weighted	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	n (weighted	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	n (weighted				
Hispanic or Latino	731	701 (13.4)	% <b>)</b> 30 (9.0)		597	581 (17.1)	% <b>)</b> 16 (18.6)		134	120 (8.2)	%) 14 (5.7)				
Other/Unknown <sup>d</sup>	476	, ,	, ,		331	, ,			145						
Month of admission				<.001				<.001				<.001			
January	852	851 (39.0)	1 (0.6)		545	544 (31.8)	1 (2.3)		307	307 (49.5)	0 (0.0)				
February	739	737 (16.4)	2 (1.5)		490	490 (14.9)	0 0.0)		249	247 (18.6)	2 (2.1)				
March	719	701 (14.3)	18 (13.0)		531	527 (16.0)	4 (7.0)		188	174 (11.7)	14 (15.0)				
April	713	674 (17.6)	39 (34.2)		472	464 (22.0)	8 (19.8)		241	210 (11.3)	31 (39.0)				
May	924	825 (9.4)	99 (31.2)		602	568 (11.3)	34 (41.8)		322	257 (6.7)	65 (27.7)				
June	785	652 (3.3)	133 (19.3)		491	446 (4.1)	45 (29.0)		294	206 (2.2)	88 (16.1)				
Code status on admission				<.001				0.51				0.17			
Full code	4,010	3,788 (84.8)	222 (74.5)		2,815	2,735 (91.3)	80 (87.4)		1,195	1,053 (75.5)	142 (70.3)				
DNR/DNI/CMO	303	256 (6.3)	47 (17.3)		49	47 (1.2)	2 (2.7)		254	209 (13.7)	45 (22.1)				
Unknown	419	396 (8.8)	23 (8.2)		267	257 (7.5)	10 (10.0)		152	139 (10.8)	13 (7.6)				
LTCF residence <sup>e</sup>	183	146 (5.5)	37 (14.5)	<.001	49	44 (1.8)	5 (5.0)	0.06	134	102 (10.9)	32 (17.7)	0.09			
Any underlying medical condition	4,319	4,040 (92.0)	279 (96.4)	0.02	2,785	2,701 (89.1)	84 (89.4)	0.95	1,534	1,339 (96.2)	195 (98.7)	0.04			
Hypertension	2,600	2,398 (59.9)	202 (70.5)	0.02	1,389	1,342 (46.4)	47 (52.7)	0.34	1,211	1,056 (79.6)	155 (76.5)	0.53			

		Adults	≥18 years			<65	≥65 years						
Category	Total	Unvaccinated n (weighted %)	•	p-value <sup>b</sup> 1	Γotal	Unvaccinated n (weighted %)	Fully vaccinated n	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n	p-value <sup>b</sup>	
		76]	(weighted %)				(weighted %)				(weighted %)		
Obesity <sup>f</sup>	2,429	2,308 (49.9)	121 (48.4)	0.76	1,815	1,769 (58.2)	46 (50.0)	0.21	614	539 (37.8)	75 (47.9)	0.10	
Chronic metabolic disease	1,907	1,765 (43.5)	142 (48.5)	0.29	1,117	1,083 (37.2)	34 (42.6)	0.41	790	682 (52.6)	108 (50.5)	0.73	
Diabetes mellitus	1,526	1,420 (36.1)	106 (38.1)	0.66	906	877 (30.2)	29 (38.9)	0.17	620	543 (44.6)	77 (37.8)	0.26	
Chronic lung disease	1,458	1,352 (30.5)	106 (39.2)	0.06	910	875 (30.1)	35 (40.8)	0.08	548	477 (31.1)	71 (38.6)	0.12	
Asthma/Reactive airway disease	683	637 (13.7)	46 (18.7)	0.15	493	472 (15.5)	21 (23.9)	0.08	190	165 (11.1)	25 (16.9)	0.17	
COPD	435	392 (9.8)	43 (14.2)	0.13	191	180 (6.6)	11 (10.2)	0.28	244	212 (14.5)	32 (15.6)	0.80	
Cardiovascular disease <sup>g</sup>	1,504	1,347 (35.6)	157 (58.6)	<.001	635	606 (20.7)	29 (31.7)	0.04	869	741 (57.3)	128 (67.5)	0.07	
Heart failure	456	399 (12.8)	57 (24.6)	0.003	187	180 (7.5)	7 (5.3)	0.37	269	219 (20.4)	50 (31.1)	0.07	
Coronary artery disease	520	462 (13.0)	58 (18.6)	0.09	159	155 (5.5)	4 (6.2)	0.85	361	307 (23.8)	54 (22.7)	0.84	
Neurologic disease	743	661 (17.2)	82 (33.0)	<.001	345	327 (10.5)	18 (22.9)	0.004	398	334 (27.0)	64 (36.4)	0.09	
Renal disease	673	584 (16.5)	89 (30.4)	<.001	274	259 (10.3)	15 (18.2)	0.05	399	325 (25.4)	74 (34.5)	0.10	
Immunosuppressive condition	511	442 (11.3)	69 (32.1)	<.001	297	275 (10.1)	22 (23.8)	<.001	214	167 (13.2)	47 (34.9)	<.001	
Solid organ malignancy	177	152 (3.8)	25 (13.7)	<.001	80	72 (2.6)	8 (8.6)	0.007	97	80 (5.6)	17 (15.4)	0.005	
Transplant	59	45 (1.8)	14 (5.5)	0.004	41	33 (1.9)	8 (9.5)	<.001	18	12 (1.8)	6 (4.2)	0.19	
Gastrointestinal or liver	289	265 (5.6)	24 (7.3)	0.35	192	181 (5.1)	11 (15.0)	0.001	97	84 (6.3)	13 (4.8)	0.53	

		Adults	s ≥18 years			<65	years		≥65 years						
Category	Total	Unvaccinated n (weighted %)		p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)	p-value <sup>b</sup>	Total	Unvaccinated n (weighted %)	Fully vaccinated n (weighted %)				
disease															
Blood disorder	164	145 (2.9)	19 (5.4)	0.03	95	90 (2.2)	5 (6.1)	0.03	69	55 (3.9)	14 (5.2)	0.46			
Rheumatologic or autoimmune disease	174	150 (3.5)	24 (8.7)	0.01	94	91 (3.2)	3 (4.3)	0.63	80	59 (3.9)	21 (10.1)	0.02			
Number of underlying conditions <sup>h</sup>				<.001				0.12				0.27			
0	444	431 (8.6)	13 (3.6)		377	369 (11.9)	8 (10.6)		67	62 (3.8)	5 (1.3)	)			
1	735	711 (14.3)	24 (6.3)		578	565 (18.3)	13 (10.8)		157	146 (8.5)	11 (4.8)				
2	1,047	993 (21.0)	54 (19.3)		760	737 (23.2)	23 (19.1)		287	256 (17.7)	31 (19.3)				
≥3	2,506	2,305 (56.1)	201 (70.8)		1,416	1,368 (46.5)	48 (59.4)		1,090	937 (70.0)	153 (74.6)				
Outcomes															
ICU admission	991	931 (20.0)	60 (21.6)	0.66	646	627 (19.2)	19 (17.7)	0.75	345	304 (21.2)	41 (22.9)	0.72			
In-hospital death	365	342 (8.4)	23 (7.5)	0.69	168	165 (5.7)	3 (3.2)	0.36	197	177 (12.3)	20 (9.0)	0.30			
Median length of stay in days (IQR)		4 (2–9)	5 (3–8)	<.001		4 (2-7)	4 (2–6)	<.001		6 (3–11)	5 (3–9)	<.001			

Abbreviations: BIPAP = bilevel positive airway pressure; CMO = comfort measures only; COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19— Associated Hospitalization Surveillance Network; CPAP = continuous positive airway pressure; DNI = do not intubate; DNR = do not resuscitate; ICU = intensive care unit; IQR = interquartile range; LTCF = long-term care facility

<sup>&</sup>lt;sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

<sup>&</sup>lt;sup>b</sup>Statistical significance for univariate analyses was determined as p<.10

<sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: Hispanic or Latino, non-Hispanic White (White), non-Hispanic Black (Black), and Other/Unknown. If ethnicity was unknown (7% of cases), non-Hispanic ethnicity was assumed.

<sup>d</sup>Includes American Indian/Alaska Native (68, 1%), Asian/Pacific Islander (240, 7%), and multiple/unknown race (168, 3%). For adults aged <65 years, the breakdown was: American Indian/Alaska Native (50, 1%), Asian/Pacific Islander (164, 7%), and multiple/unknown race (117, 4%). For those aged ≥65 years, American Indian/Alaska Native (18, 1%), Asian/Pacific Islander (76, 7%), and multiple/unknown race (51, 2%).

<sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>f</sup>Obesity is defined as calculated body mass index (BMI) ≥30 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes.

<sup>&</sup>lt;sup>g</sup>Cardiovascular disease excludes hypertension.

<sup>&</sup>lt;sup>h</sup>Overall condition categories as defined in Supplementary Table 1.

# **Figures**

Figure 1. Multivariable model<sup>a</sup> assessing factors associated with full vaccination status in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 − June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged A) <65 years and B) aged ≥65 years — COVID-NET, 13 States<sup>b</sup> A)

	Unv	accinated	Fully	vaccinated	Una	djusted Risk Ratio	-	ed Risk Itio										
Demographic characteristic	N	Weighted %	N	Weighted %	RR	(95% CI)	aRR	(95% CI)	p- value	Standard error	_							
Age (in years)							1	(0.98, 1.02)	0.81	0.0093		•						
Sex								,			_							
Male	1,576	50.3	40	43.7	0.77	(0.55, 1.09)	0.77	(0.57, 1.05)	0.10	0.1537								
Female	1,463	49.7	52	56.3	Ref		Ref											
Race and Hispanic ethnicity <sup>c</sup>																		
White	1347	37.9	60	61.7	Ref		Ref				•	-						
Black	785	33.4	11	14.8	0.28	(0.09, 0.81)	0.26	(0.09, 0.75)	0.01	0.5394	-	•						
Hispanic or Latino	581	17.1	16	18.6	0.68	(0.5, 0.92)	0.76	(0.54, 1.07)	0.12	0.1741		-	•					
Other/Unknown <sup>d</sup>	326	11.7	5	4.9	0.26	(0.1, 0.72)	0.33	(0.12, 0.94)	0.04	0.5272		•	_					
LTCF residence <sup>e</sup>	44	1.8	5	5.0	2.85	(1.23, 6.6)	1.72	(0.67, 4.43)	0.26	0.4834		•						
Underlying medical condition													•					
Chronic lung disease	875	30.1	35	40.8	1.59	(1.1, 2.3)	1.26	(0.99, 1.6)	0.06	0.1216			•				_	
Cardiovascular disease f	606	20.7	29	31.7	1.77	(0.93, 3.36)	1.17	(0.64, 2.15)	0.60	0.3094				•—				
Neurologic disease	327	10.5	18	22.9	2.5	(1.64, 3.8)	1.62	(1, 2.61)	0.05	0.2433			•			_		
Renal disease	259	10.3	15	18.2	1.92	(1.02, 3.61)	1.56	(0.79, 3.09)	0.20	0.3484	0	1	2	3		4	5	_
Immunosuppressive condition	275	10.1	22	23.8	2.74	(1.24, 6.03)	2	(0.85, 4.72)	0.11	0.4384			а	aRR (95	% CI)			

Gastrointestinal or liver disease	181	5.1	11	15.0	3.18	(1.38, 7.36)	2.35	(1.02, 5.4)	0.04	0.425			
Blood disorder	90	2.2	5	6.1	2.83	(1.09, 7.33)	1.7	(0.71, 4.12)	0.24	0.4496			

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network; LTCF = long-term care facility <sup>a</sup>Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with independent covariance structure. Statistical significance was determined at p<0.05.

<sup>&</sup>lt;sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>&</sup>lt;sup>c</sup>Race/ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (7%), non-Hispanic ethnicity was assumed.

<sup>&</sup>lt;sup>d</sup>Includes American Indian/Alaska Native (50), Asian/Pacific Islander (164), and multiple/unknown race (117).

<sup>&</sup>lt;sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>&</sup>lt;sup>f</sup>Cardiovascular disease excludes hypertension.

	Unva	accinated		Fully cinated	Una	Unadjusted Risk Ratio		d Risk Ratio									
Demographic characteristic	N	Weight ed %	N	Weight ed %	RR	(95% CI)	aRR	(95% CI)	p- value	Standard error	-						
Age (in years)							1.03	(1, 1.07)	0.04	0.0162							
Sex								( , ,									
Male	699	53.5	105	51.1	0.91	(0.68, 1.23)	0.84	(0.64, 1.11)	0.22	0.1397		•					
Female	702	46.5	95	48.9	Ref		Ref	,									
Race and Hispanic ethnicity <sup>c</sup>																	
White	916	57.4	144	67.8	Ref		Ref										
Non-Hispanic Black	238	23.4	24	18.5	0.68	(0.46, 1)	0.78	(0.51, 1.19)	0.25	0.2171	_	•	_				
Hispanic or Latino	120	8.2	14	5.7	0.61	(0.27, 1.37)	0.81	(0.36, 1.81)	0.61	0.4092	_	•					
Other/Unknown <sup>d</sup>	127	11	18	8	0.63	(0.38, 1.07)	0.65	(0.35, 1.23)	0.18	0.3227							
LTCF residence	102	10.9	32	17.7	1.69	(1.21, 2.37)	1.21	(0.86, 1.7)	0.27	0.1731			•	-			
Underlying medical condition																	
Obesity <sup>f</sup>	539	37.8	75	47.9	1.48	(0.93, 2.33)	1.6	(1.02, 2.5)	0.04	0.2282		-					
Chronic lung disease	477	31.1	71	38.6	1.37	(0.94, 2)	1.25	(0.81, 1.94)	0.31	0.2218			_				
Cardiovascular disease <sup>g</sup>	741	57.3	128	67.5	1.52	(0.9, 2.55)	1.12	(0.69, 1.82)	0.65	0.2487			_	<b>—•</b>			
Neurologic disease	334	27	64	36.4	1.51	(1.12, 2.05)	1.35	(0.98, 1.86)	0.07	0.1647		•					
Renal disease	325	25.4	74	34.5	1.51	(1.09, 2.09)	1.24	(0.8, 1.92)	0.34	0.223	0	1	2	3	4	5	6
Immunosuppressive condition	167	13.2	47	34.9	3.21	(2.21, 4.67)	3.16	(1.96, 5.11)	<.001	0.245			aF	RR (95%	· CI)		
Rheumatologic or autoimmune disease	59	3.9	21	10.1	2.55	(1, 6.52)	1.3	(0.56, 3.04)	0.54	0.4317	T						

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network; LTCF = long-term care facility a Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with independent covariance structure

<sup>&</sup>lt;sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>&</sup>lt;sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (7%), non-Hispanic ethnicity was assumed.

<sup>&</sup>lt;sup>d</sup>Includes American Indian/Alaska Native (18), Asian/Pacific Islander (76), and multiple/unknown race (51)


<sup>&</sup>lt;sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.


<sup>&</sup>lt;sup>†</sup>Obesity is defined as calculated body mass index (BMI) ≥30 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes.

<sup>&</sup>lt;sup>g</sup>Cardiovascular disease excludes hypertensio

Figure 2. Age-adjusted population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults aged ≥18 years admitted January 24–July 24, 2021, <sup>b</sup> A) cumulative and B) by week of admission — COVID-NET, 13 States<sup>c</sup>

A)






Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network

<sup>&</sup>lt;sup>a</sup>Number of patients with laboratory-confirmed COVID-19—associated hospitalizations per 100,000 population.


<sup>&</sup>lt;sup>b</sup> COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.


<sup>&</sup>lt;sup>c</sup>California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

Figure 3. Age-specific population-based rates<sup>a</sup> of COVID-19-associated hospitalizations among unvaccinated and fully vaccinated adults aged ≥18 years admitted January 24–July 24, 2021, <sup>b</sup> by week of admission and aged A) 18–49 years B) 50–64 years and C) ≥65 years — COVID-NET, 13 States<sup>c</sup>. Rates are shown with 95% confidence intervals.









Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network

<sup>&</sup>lt;sup>a</sup>Number of patients with laboratory-confirmed COVID-19—associated hospitalizations per 100,000 population. Lighter shades around each line represent 95% confidence intervals

<sup>&</sup>lt;sup>b</sup> COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.

<sup>&</sup>lt;sup>c</sup> California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

### **Supplementary Content**

### **Supplementary Tables:**

## Supplement Table 1. Categorization of Underlying Medical Conditions<sup>a</sup>

Chronic Lung Disease	a Anti-ve tula evaluación
Chronic Lung Disease	Active tuberculosis
	Asbestosis
	Asthma/Reactive airway disease
	Bronchiectasis
	Bronchiolitis obliterans
	Chronic bronchitis
	Chronic respiratory failure
	Cystic fibrosis
	Emphysema/Chronic Obstructive Pulmonary Disease
	Interstitial lung disease
	Obstructive sleep apnea
	Oxygen dependent
	Pulmonary fibrosis
	Restrictive lung disease
	Sarcoidosis
Diabetes Mellitus	
Other Chronic Metabolic Disease (except	Adrenal Disorders (Addison's, Adrenal Insufficiency, Cushing
Diabetes Mellitus)	Syndrome, Congenital Adrenal Hyperplasia)
	Glycogen or other storage diseases
	Hyper/Hypo function of pituitary gland
	Inborn errors of metabolism
	Metabolic Syndrome
	,
	Parathyroid Dysfunction (Hyperparathyroidism,  Hyperparathyroidism)
	Hypoparathyroidism)
	Thyroid dysfunction (Grave's disease, Hashimoto's Disease,      Hypothyroidism, Hypothyroidism)
Blood Disordors/Homotologic Conditions	Hyperthyroidism, Hypothyroidism)
Blood Disorders/Hematologic Conditions	Alpha thalassemia     Andertic and are a series.
	Aplastic anemia
	Beta thalassemia
	Coagulopathy (Factor V Leiden, Von Willebrand Disease)
	Hemoglobin S-beta thalassemia
	Leukopenia
	Myelodysplastic syndrome
	Neutropenia
	Pancytopenia
	Polycythemia vera
	Sickle cell disease
	Splenectomy/Asplenia
	Thrombocytopenia
Cardiovascular Disease (except	Aortic aneurysm, history of
hypertension)	Aortic/Mitral/Tricuspid/Pulmonic valve replacement, history of
	Aortic regurgitation
	Aortic stenosis
	Atherosclerotic cardiovascular disease
	Atrial fibrillation
	, tation indimension

	Atrioventricular blocks
	Automated implantable devices/Pacemaker     The second secon
	Bundle branch block
	<ul> <li>Cardiomyopathy</li> </ul>
	Carotid stenosis
	<ul> <li>Cerebral vascular accident/Incident/Stroke, history of</li> </ul>
	Congenital heart disease
	<ul> <li>Coronary artery bypass grafting, history of</li> </ul>
	Coronary artery disease
	<ul> <li>Deep vein thrombosis, history of</li> </ul>
	<ul> <li>Heart failure/congestive heart failure</li> </ul>
	<ul> <li>Myocardial infarction, history of</li> </ul>
	Mitral regurgitation
	Mitral stenosis
	Peripheral artery disease
	Peripheral vascular disease
	Pulmonary embolism, history of
	Pulmonary hypertension
	Pulmonic regurgitation
	Pulmonic stenosis
	Transient ischemic attack, history of
	Tricuspid regurgitation
	Tricuspid stenosis
	Ventricular fibrillation, history of
	Ventricular tachycardia, history of
Hypertension	, ,
Neurologic Disorder	Amyotrophic lateral sclerosis
, and the second	Cerebral palsy
	Cognitive dysfunction
	Dementia/Alzheimer's disease
	Developmental delay
	Down syndrome/Trisomy 21
	Edward's syndrome/Trisomy 18
	Epilepsy/seizure/seizure disorder
	Mitochondrial disorder
	Multiple sclerosis
	Muscular dystrophy
	Myasthenia gravis
	Neural tube defects/Spina bifida
	Neuropathy
	Parkinson's disease
	Plegias/Paralysis/Quadriplegia
	Scoliosis/Kyphoscoliosis
	Traumatic brain injury, history of
History of Guillain Barra Syndroma	Traumatic brain injury, mstory or
History of Guillain-Barre Syndrome	AIDS or CD4 count <200
Immunocompromised Conditions	AIDS or CD4 count <200     Complement deficiency
	Complement deficiency     Craft vs. host disease.
	Graft vs. host disease     HIV Infection
	HIV Infection     Immunoglobulin deficiency/Immunodeficiency/
	Immunoglobulin deficiency/Immunodeficiency

	• Immunosuppressive therapy (within the last 12 months prior to admission)
	• Leukemia <sup>b</sup>
	• Lymphoma/Hodgkins/Non-Hodgkins <sup>b</sup>
	Metastatic cancer <sup>b</sup>
	Multiple myeloma <sup>b</sup>
	Solid organ malignancy <sup>b</sup>
	• Steroid therapy (within 2 weeks of admission)
	• Transplant, hematopoietic stem cell (Bone marrow transplant,
	peripheral stem cell transplant), history of
	Transplant, solid organ, history of
Renal Disease	Chronic kidney disease/chronic renal insufficiency
	Dialysis
	End stage renal disease
	Glomerulonephritis
	Nephrotic syndrome
	Polycystic kidney disease
Gastrointestinal/Liver Disease	Alcoholic hepatitis
	Autoimmune hepatitis
	Barrett's esophagitis
	Chronic liver disease
	Chronic pancreatitis
	Cirrhosis/End stage liver disease
	Crohn's disease
	Esophageal varices
	Esophageal strictures
	Hepatitis B, chronic
	Hepatitis C, chronic
	Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis
	Ulcerative colitis
Rheumatologic/Autoimmune Conditions	Ankylosing spondylitis
	Dermatomyositis
	Juvenile idiopathic arthritis
	Kawasaki disease
	Microscopic polyangiitis
	Polyarteritis nodosum
	Polymyalgia rheumatica
	• Polymyositis
	Psoriatic arthritis
	Rheumatoid arthritis
	Systemic Lupus Erythematosus/Lupus
	Systemic sclerosis
	Takayasu arteritis
	Temporal/Giant Cell arteritis
	Vasculitis, other
Other, specify	Post-partum (2 weeks or less)
	Feeding tube dependent
	Tracheostomy dependent/ventilator dependent
	Wheelchair dependent
	Free text field for other underlying medical conditions that

	were not specified above	were not specified above	

<sup>&</sup>lt;sup>a</sup>Underlying medical conditions were selected before hospitalization surveillance began.

<sup>&</sup>lt;sup>b</sup>Current/in treatment or diagnosed in previous 12 months

Supplementary Table 2. Characteristics of fully vaccinated cases who had a prior positive SARS-CoV-2 test compared with fully vaccinated cases with no evidence of prior infection, among adults ≥ 18 years admitted January 1–June 30, 2021 — COVID-NET, 13 States<sup>a</sup>

Characteristics	No evidence of prior infection n=292	Prior positive test n=47 <sup>b</sup>	p-value <sup>c</sup>
Age group			0.82
18-49 years	29 (8.7)	4 (5.9)	
50-64 years	63 (16.3)	11 (18.6)	
≥65 years	200 (75.0)	32 (75.5)	
Sex			0.77
Male	145 (49.3)	26 (45.4)	
Female	147 (50.7)	21 (54.6)	
Race and Hispanic ethnicity <sup>d</sup>			
White	204 (66.3)	33 (69.9)	0.10
Black	35 (17.5)	7 (15.5)	
Hispanic or Latino	30 (9.0)	4 (9.4)	
Other/Unknown	23 (7.2)	3 (5.2)	
Month of admission		, ,	0.08
January	1 (0.6)	0 (0.0)	
February	2 (1.6)	0 (0.0)	
March	18 (13.0)	5 (37.1)	
April	39 (34.2)	7 (21.8)	
May	99 (31.2)	13 (22.7)	
June	133 (19.3)	22 (18.4)	
Code status on admission			0.62
Full code	222 (74.5)	36 (82.5)	
DNR/DNI/CMO	47 (17.3)	9 (10.9)	
Unknown	23 (8.2)	2 (6.6)	
LTCF residence <sup>e</sup>	37 (14.5)	16 (31.6)	0.07
Any symptom	250 (88.2)	35 (65.0)	0.02
Hypertension	202 (70.5)	33 (75.6)	0.61
Obesity <sup>f</sup>	121 (48.4)	15 (46.5)	0.90
Severe obesity <sup>g</sup>	34 (14.1)	5 (8.9)	0.39
Chronic metabolic disease	142 (48.5)	23 (63.6)	0.20
Diabetes mellitus	106 (38.1)	18 (53.5)	0.23
Chronic lung disease	106 (39.2)	23 (43.7)	0.72
Asthma/Reactive airway disease	46 (18.7)	10 (18.8)	0.99
COPD	43 (14.2)	11 (21.7)	0.36
Cardiovascular disease <sup>h</sup>	157 (58.6)	30 (78.0)	0.04
Heart failure	57 (24.6)	17 (34.1)	0.40
Coronary artery disease	58 (18.6)	12 (19.1)	0.94
Neurologic disease	82 (33.0)	18 (31.9)	0.92
Renal disease	89 (30.4)	14 (21.2)	0.32

Characteristics	No evidence of prior infection	Prior positive test n=47 <sup>b</sup>	p-value <sup>c</sup>
	n=292		
Immunosuppressive condition	69 (32.1)	6 (9.8)	0.006
Gastrointestinal or liver disease	24 (7.3)	6 (9.6)	0.63
Blood disorder	19 (5.4)	4 (2.8)	0.30
Rheumatologic or autoimmune disease	24 (8.7)	1 (3.0)	0.28
Number of underlying conditions			0.07
0	13(3.6)	0 (0.0)	
1	24 (6.3)	9 (17.3)	
2	54 (19.3)	5 (5.1)	
≥3	201 (70.8)	33 (77.7)	
ICU admission	60 (21.6)	7 (11.4)	0.22
In-hospital death	23 (7.5)	2 (1.2)	0.006
ICU admission or in-hospital death	66 (23.3)	8 (12.0)	0.18
Median length of stay in days (IQR)	5 (3-8)	5 (2-14)	<.001
ICU admission, invasive mechanical	69 (23.9)	10 (34.3)	0.47
ventilation, or in-hospital death			
Invasive mechanical ventilation	25 (8.7)	3 (23.0)	0.23
Vasopressor use	29 (11.0)	5 (4.9)	0.19
BIPAP or CPAP use	44 (14.5)	4 (6.7)	0.31
Renal Replacement Therapy	14 (3.1)	2 (1.2)	0.23

Abbreviations: BIPAP = bilevel positive airway pressure; CMO = comfort measures only; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network; CPAP = continuous positive airway pressure; DNI = do not intubate; DNR = do not resuscitate; ICU = intensive care unit; IQR = interquartile range; LTCF = long-term care facility; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

<sup>&</sup>lt;sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

<sup>&</sup>lt;sup>b</sup>Five cases with hospitalization not primarily associated with COVID-19 illness were excluded

Statistical significance for univariate analyses was determined as p<.10

<sup>&</sup>lt;sup>d</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: Hispanic or Latino, non-Hispanic White (White), non-Hispanic Black (Black), and Other/Unknown. If ethnicity was unknown, non-Hispanic ethnicity was assumed.

<sup>&</sup>lt;sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term caute care hospitals, residential care facilities or other long-term care facilities.

<sup>&</sup>lt;sup>f</sup>Obesity is defined as calculated body mass index (BMI) ≥30 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes.

<sup>&</sup>lt;sup>g</sup>Severe obesity is defined as calculated body mass index (BMI) ≥40 kg/m2, and if BMI is missing, by International Classification of Diseases discharge diagnosis codes.

<sup>&</sup>lt;sup>h</sup>Cardiovascular disease excludes hypertension

Overall condition categories as defined in Supplementary Table 1

Supplementary Table 3A. Multivariable model<sup>a</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged <65 years — COVID-NET, 13 States<sup>b</sup>

Category	No severe illness	Have severe illness	Unadjusted	Adjusted risk	p-value	Standard
	n (weighted %)	n (weighted %)	risk ratio	ratio		error
Race and Hispanic ethnicity <sup>c</sup>						
White	1,096 (37.2)	311 (42.6)	R	R	R	R
Black	653 (34.9)	143 (26.0)	0.7 (0.5, 1)	0.8 (0.6, 1.1)	0.14	0.1716
Hispanic or Latino	475 (16.7)	122 (18.4)	1 (0.8, 1.2)	1 (0.8, 1.3)	0.78	0.1106
Other/Unknown <sup>d</sup>	249 (11.2)	82 (12.9)	1 (0.8, 1.2)	1.1 (0.9, 1.3)	0.20	0.0815
Sex						
Male	1,237 (49.3)	379 (53.9)	1.2 (1, 1.3)	1.2 (1, 1.3)	0.02	0.0626
Female	1,236 (50.7)	279 (46.1)	R	R	R	R
Age (in years)				1 (1, 1)	0.002	0.0039
Unvaccinated	2,400 (98.7)	639 (98.9)	R	R	R	R
Fully vaccinated	73 (1.3)	19 (1.1)	0.9 (0.7, 1.2)	0.8 (0.6, 1.0)	0.028	0.1283
LTCF residence <sup>e</sup>	34 (1.7)	15 (2.1)	1.2 (0.6, 2.2)	0.9 (0.5, 1.7)	0.74	0.3428
Underlying medical condition						
Chronic metabolic disease	829 (35.1)	288 (46.0)	1.4 (1.2, 1.7)	1.3 (1.1, 1.5)	0.001	0.0823
Chronic lung disease	702 (29.4)	208 (33.6)	1.2 (1, 1.4)	1.1 (0.9, 1.3)	0.48	0.1052
Cardiovascular disease <sup>f</sup>	462 (19.3)	173 (27.1)	1.4 (1.1, 1.8)	1.2 (1, 1.6)	0.11	0.1316
Neurologic disease	261 (10.2)	84 (12.6)	1.2 (1, 1.4)	1 (0.9, 1.2)	0.78	0.0881
Renal disease	191 (9.6)	83 (13.6)	1.4 (1, 1.8)	1.1 (0.9, 1.4)	0.31	0.1202
Immunosuppressive condition	227 (9.7)	70 (12.4)	1.2 (1, 1.5)	1.2 (0.9, 1.5)	0.29	0.1362
Gastrointestinal or liver disease	140 (4.7)	52 (7.8)	1.5 (1.2, 2)	1.4 (1, 2)	0.04	0.1736

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network; LTCF = long-term care facility <sup>a</sup>Log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with exchangeable covariance structure

<sup>&</sup>lt;sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>&</sup>lt;sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (4%), non-Hispanic ethnicity was assumed.

45

<sup>d</sup>Includes American Indian/Alaska Native, Asian/Pacific Islander, and multiple/unknown race.

<sup>&</sup>lt;sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing facilities, long-term care facilities, long-term acute care hospitals, residential care facilities or other long-term care facilities.

<sup>&</sup>lt;sup>f</sup>Cardiovascular disease excludes hypertension.

Supplementary Table 3B. Multivariable model<sup>a</sup> assessing factors associated with severe COVID-19 diseases (ICU, in-hospital death) in hospitalized adults with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, restricting to those with COVID-19-associated hospitalization as the likely primary reason for admission, among those aged ≥65 years — COVID-NET, 13 States<sup>b</sup>

Category	No severe illness n (weighted %)	Have severe illness n (weighted %)	Unadjusted risk ratio	Adjusted risk ratio	p-value	Standard error
Race and Hispanic ethnicity <sup>c</sup>						
White	829 (60.5)	231 (50.0)	R	R	R	R
Black	185 (21.5)	77 (28.4)	1.4 (0.9, 2.3)	1.6 (1, 2.6)	0.05	0.2433
Hispanic or Latino	89 (7.4)	45 (10.1)	1.4 (1, 2.1)	1.6 (1.2, 2.3)	0.005	0.1736
Other/Unknown <sup>d</sup>	101 (10.6)	44 (11.5)	1.2 (0.9, 1.7)	1.3 (0.9, 1.8)	0.15	0.1722
Sex						
Male	576 (52.5)	228 (55.9)	1.1 (0.8, 1.5)	1.1 (0.8, 1.4)	0.47	0.1326
Female	628 (47.5)	169 (44.1)	R	R	R	R
Age (in years)				1 (1, 1)	0.34	0.0086
Unvaccinated	1,051 (94.8)	350 (94.6)	R	R	R	R
Fully vaccinated	153 (5.2)	47 (5.4)		1.1 (0.7, 1.6)	0.80	0.2167
LTCF residence <sup>e</sup>	90 (10.3)	44 (14.2)	1.3 (0.9, 1.9)	1.5 (1, 2.2)	0.06	0.2019
Underlying medical condition						
Neurologic disease	304 (29.0)	94 (22.5)	0.8 (0.6, 1)	0.7 (0.5, 0.9)	0.02	0.1486
Immunosuppressive condition	155 (13.0)	59 (18.5)	1.4 (1.1, 1.7)	1.4 (1.1, 1.7)	0.002	0.1097

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network; LTCF = long-term care facility a log-linked Poisson Regression using generalized estimating equations (GEE) clustered on site with exchangeable covariance structure

<sup>&</sup>lt;sup>b</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

<sup>&</sup>lt;sup>c</sup>Race and Hispanic ethnicity: Data on race and ethnicity were categorized as follows: non-Hispanic White (White), non-Hispanic Black (Black), Other/Unknown. If ethnicity was unknown (7% of cases), non-Hispanic ethnicity was assumed.

<sup>&</sup>lt;sup>d</sup>Includes American Indian/Alaska Native, Asian/Pacific Islander, and multiple/unknown race

<sup>&</sup>lt;sup>e</sup>Long-term care facility (LTCF) residence was defined as residence in rehabilitation facilities, assisted living/residential care, group homes, nursing homes, skilled nursing.

# Supplementary Table 4. Rate ratios of COVID-19-associated hospitalizations in unvaccinated vs vaccinated patients among all adults aged ≥18 years and by age group <sup>a</sup>, January 24–July 24, 2021<sup>b</sup> – COVID-NET, 13 States<sup>c</sup>

	Rate ratio of hospitalizations	Rate ratio,	Rate ratio,	Rate ratio,
MMWR week ending	all adults ≥18 years (age-adjusted)	18–49 years	50-64 years	≥65 years
1/30/2021	21	_	7	
2/6/2021	13	_	-	7
2/13/2021	8	10	26	5
	8			4
2/20/2021		23	21	
2/27/2021	6	15	23	4
3/6/2021	14	21	15	11
3/13/2021	10	52	14	6
3/20/2021	12	15	12	11
3/27/2021	20	21	22	18
4/3/2021	15	75	15	11
4/10/2021	17	45	22	13
4/17/2021	28	18	53	25
4/24/2021	24	40	51	16
5/1/2021	22	33	31	17
5/8/2021	31	51	33	26
5/15/2021	26	32	49	18
5/22/2021	19	13	23	21
5/29/2021	21	19	16	25
6/5/2021	29	24	78	23
6/12/2021	15	17	21	13
6/19/2021	17	13	25	16
6/26/2021	17	12	16	22
7/3/2021	14	13	18	12
7/10/2021	12	19	13	10
7/17/2021	17	17	20	15
7/24/2021	19	20	25	16
Cumulative	17	23	22	13
Range	6–31	10-75	7–78	4-26

Abbreviations: COVID-19 = coronavirus disease 2019; COVID-NET = COVID-19—Associated Hospitalization Surveillance Network

<sup>&</sup>lt;sup>a</sup>Age-specific rate ratios could not be calculated for weeks during which zero vaccinated cases were reported and are represented by a dash (-).

<sup>&</sup>lt;sup>b</sup> COVID-NET hospitalization data are preliminary and subject to change as more data become available. In particular, rates for recent hospital admissions are subject to lag.

<sup>&</sup>lt;sup>c</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.

#### **Supplementary Figures:**

Supplementary Figure 1. Selection of cases for analysis of adults ≥18 years with laboratory-confirmed COVID-19-associated hospitalization admitted January 1 – June 30, 2021, by vaccination status — COVID-NET, 13 States<sup>a</sup>

**67,311** hospitalized adults ≥18 years admitted January 1–June 30, 2021 with positive SARS-CoV-2 test within ≤14 days of admission

**35,846** hospitalized adults ≥18 years linked to state vaccination registries (Vaccine Sample<sup>b</sup>)

- Unvaccinated (n = 30,967)
- One dose of vaccine <14 days prior to positive SARS-CoV-2 test (n = 1,791)
- Partially vaccinated<sup>c</sup> (n = 1,753)
- Fully vaccinated (n = 1,255)
- Vaccination status unknown (n = 80)

**6,115** hospitalized adults ≥18 years with chart review

Excluded 1,383 hospitalized adults ≥18 years
 One dose of vaccine <14 days prior to positive SARS-CoV-2 test (n = 282)</li>
 Partially vaccinated (n = 286) <sup>c</sup>
 Vaccination status unknown (n = 14)

Incomplete data (n = 33)

• Evidence of SARS-CoV-2 infection prior to full vaccination (n = 52)

Admitted primarily due to non-COVID-19-associated reasons<sup>d</sup> (n = 716)

Unvaccinated: 670

Vaccinated: 46

**4,732** hospitalized adults ≥18 years admitted due to COVID-19 related illness (Comparison Sample)<sup>e</sup>:

- Unvaccinated (n = 4,440)
- Fully vaccinated (n = 292)

Abbreviation: COVID-NET, Coronavirus Disease 2019 (COVID-19-associated Hospitalization Surveillance Network)

<sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah

NOTE: For both the vaccine sample and the analytic sample, sampling weights were created based on the probability of selection. Weights were adjusted for non-response, adjusted to population catchment totals based on combinations of surveillance site, time period of admission, age, sex, and race/ethnicity via published raking procedures, and trimmed to reduce variability, as previously described.<sup>1</sup>


bVaccine sample includes representative random sample from each site (sampled cases) as well as all non-sampled cases if all cases from a single site and age strata had vaccination status available.

<sup>&</sup>lt;sup>c</sup>Received one dose of two-dose series (for Pfizer/BioNTech and Moderna)

dincludes cases admitted due to obstetrics/labor and delivery admission (316), surgery (103), psychiatric admission needing acute medical care (99), trauma (124), "other" (2) and unknown reason (72).

<sup>&</sup>lt;sup>e</sup>Comparison sample includes only those sampled cases with complete medical chart abstraction who were either unvaccinated or fully vaccinated; vaccinate cases who had evidence of prior SARS-CoV-2 infection prior to qualifying as fully vaccinated were excluded.


Supplementary Figure 2. Proportion of adults ≥18 years with COVID-19-associated hospitalizations admitted January 1 – June 30, 2021 who are fully vaccinated, by age group and month of admission – COVID-NET, 13 States<sup>a</sup>




<sup>&</sup>lt;sup>a</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah


Supplementary Figure 3. COVID-NET catchment population by vaccination status <sup>a</sup> and week, used as denominator in population-based-rate calculations <sup>b</sup> among A) all adults ≥18 years, B) 18–49 years, C) 50–64 years, and D) ≥65 years, January 24–July 24, 2021—COVID-NET, <sup>c</sup> 13 States <sup>d</sup>


### A)



### B)







<sup>&</sup>lt;sup>a</sup> Partially vaccinated persons are excluded.

<sup>&</sup>lt;sup>b</sup> Data from CDC immunization information systems county-level data for the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET) surveillance area.

<sup>&</sup>lt;sup>c</sup> The COVID-NET hospitalization data are preliminary and subject to change as more data become available. Rates for recent hospital admissions are subject to lag.

<sup>&</sup>lt;sup>d</sup>California, Connecticut, Colorado, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah